Moderna is trading 7.35% down at $134.47 after no new company-specific announcement was identified for August 24, 2026.
- The decline follows an exceptionally volatile week surrounding positive Phase 3 melanoma-vaccine results with Merck.
- Moderna rose 8.86% on August 21 after earlier sharp repricing, while broader markets are only modestly lower.
- The immediate catalyst remains unclear, indicating an unsettled post-news move rather than a confirmed new development.